Bayer says Xofigo/Xtandi combo shows overall survival benefit in prostate cancer
2026-02-26 14:36:15 ET
More on Bayer
- Bayer Aktiengesellschaft (BAYRY) Discusses Roundup Class Settlement Agreement and Implications for U.S. Glyphosate Litigation Transcript
- Bayer Aktiengesellschaft (BAYRY) Discusses OCEANIC-STROKE Phase III Results and Asundexian in Secondary Stroke Prevention - Slideshow
- Bayer Aktiengesellschaft (BAYRY) Discusses OCEANIC-STROKE Phase III Results and Asundexian in Secondary Stroke Prevention Transcript
- Bayer sues Johnson & Johnson over prostate cancer drug claims
- Bayer stumbles as investors question plan to settle Roundup litigation
Read the full article on Seeking Alpha
For further details see:
Bayer says Xofigo/Xtandi combo shows overall survival benefit in prostate cancerNASDAQ: ALPMF
ALPMF Trading
13.33% G/L:
$15.90 Last:
525 Volume:
$15.90 Open:



